Chemed (CHE) Aperçu de l'action
Chemed Corporation fournit des services de soins palliatifs aux patients par l'intermédiaire d'un réseau de médecins, d'infirmières diplômées, d'aides à domicile, de travailleurs sociaux, de membres du clergé et de bénévoles, principalement aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 1/6 |
| Performances passées | 2/6 |
| Santé financière | 3/6 |
| Dividendes | 0/6 |
CHE Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Chemed Corporation Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$509.34 |
| Plus haut sur 52 semaines | US$517.74 |
| Plus bas sur 52 semaines | US$365.21 |
| Bêta | 0.52 |
| Variation sur 1 mois | 9.94% |
| Variation sur 3 mois | 20.95% |
| Variation sur 1 an | 9.28% |
| Variation sur 3 ans | -2.25% |
| Variation sur 5 ans | 6.99% |
| Évolution depuis l'introduction en bourse | 4,402.45% |
Nouvelles et mises à jour récentes
CHE: Share Repurchases And Steady Margins Will Support Measured Future Returns
Analysts have modestly raised their price target for Chemed to $474.0 from $446.5. This change reflects updated views on fair value, profit margins, and the P/E multiple they consider appropriate for the stock. What’s in the News for Chemed Chemed Corporation (NYSE: CHE) was removed from the Russell Small Cap Comp Growth Benchmark, according to index constituent change disclosures.
CHE: Strong Q1 Results And Buybacks Support Balanced Future Return Potential
Analysts have revised their price target on Chemed to $500 from $580, reflecting updated assumptions for slightly higher discount rates, revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for Chemed Chemed reported Q1 revenue of $657.5 million, which was 1.6% higher year over year and 1.2% above analyst expectations, according to recent earnings coverage.CHE: Share Repurchases And Stable Margins Will Support Balanced Future Returns
Analysts have kept their Chemed price target essentially unchanged at about $446.50, with only minimal tweaks to underlying assumptions such as revenue growth, profit margin, and future P/E to reflect updated modeling rather than a shift in overall outlook. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.Recent updates
CHE: Share Repurchases And Steady Margins Will Support Measured Future Returns
Analysts have modestly raised their price target for Chemed to $474.0 from $446.5. This change reflects updated views on fair value, profit margins, and the P/E multiple they consider appropriate for the stock. What’s in the News for Chemed Chemed Corporation (NYSE: CHE) was removed from the Russell Small Cap Comp Growth Benchmark, according to index constituent change disclosures.CHE: Strong Q1 Results And Buybacks Support Balanced Future Return Potential
Analysts have revised their price target on Chemed to $500 from $580, reflecting updated assumptions for slightly higher discount rates, revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for Chemed Chemed reported Q1 revenue of $657.5 million, which was 1.6% higher year over year and 1.2% above analyst expectations, according to recent earnings coverage.CHE: Share Repurchases And Stable Margins Will Support Balanced Future Returns
Analysts have kept their Chemed price target essentially unchanged at about $446.50, with only minimal tweaks to underlying assumptions such as revenue growth, profit margin, and future P/E to reflect updated modeling rather than a shift in overall outlook. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.CHE: Ongoing Buybacks And Stable Margins Will Support Balanced Future Returns
Analysts have nudged their price target on Chemed higher to $446.50 from $443, reflecting updated assumptions around slightly stronger revenue growth, a modestly higher discount rate, stable profit margins, and a lower future P/E multiple. What's in the News Chemed reported that from January 1, 2026 to March 31, 2026, it repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.CHE: Ongoing Buybacks And Earnings Guidance Will Support Balanced Future Returns
Analysts now see Chemed’s fair value holding at $443, with updated assumptions for revenue growth of 6.52%, a profit margin of 12.54%, and a future P/E of 15.49x shaping their refreshed price target rationale. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares for $197.7 million, representing 3.65% of its shares under the long running buyback program announced in February 2011 (Key Developments).CHE: Expanded Buybacks And Earnings Guidance Will Support Stronger Future Returns
Analysts have kept their price target for Chemed steady at $443. This reflects updated assumptions around slightly different revenue growth, profit margin and future P/E inputs that do not materially change their overall valuation view.CHE: Expanded Buybacks And Higher Margins Will Support Stronger Future Returns
Analysts have maintained Chemed's price target at $443, citing updated assumptions for profit margin and forward P/E as key factors behind the reaffirmed view. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, with projected earnings per diluted share in a range of $23.25 to $24.25, excluding certain non cash items such as stock option expenses, tax benefits from stock option exercises, litigation costs and other discrete items (corporate guidance).CHE: Revised Outlook And Ongoing Buybacks Will Shape Balanced Future Returns
Analysts have revised their price target on Chemed to $443.00 from $555.50, reflecting updated views on revenue growth, profit margins, and the P/E multiple they consider appropriate for the stock. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, projecting earnings per diluted share, excluding specified non cash and discrete items, in a range of $23.25 to $24.25 (company guidance).Repositioned Hospice Mix And Aging Demographics Will Support Stronger Long Term Performance
Catalysts About Chemed Chemed operates VITAS Healthcare, a large hospice provider, and Roto-Rooter, a national plumbing and water restoration service business. What are the underlying business or industry changes driving this perspective?CHE: Stable Margins And Expanded Buybacks Will Support Future Upside
Analysts maintained Chemed's price target at $555.50, citing unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News On February 13, 2026, Chemed increased its equity buyback authorization by US$300 million to a total of US$3.05 billion under its existing repurchase program (Key Developments).CHE: Stable Margins And Consistent Assumptions Will Support Future Upside
Analysts have maintained their fair value estimate for Chemed at US$555.50 per share, with only small adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a marginally updated price target narrative. Valuation Changes Fair Value: Kept unchanged at US$555.50 per share, indicating no revision to the central valuation output.CHE: Share Buybacks And Margin Outlook Will Support Future Upside
Analysts now see Chemed's fair value at US$555.50, down from US$582.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions.Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results
It's been a good week for Chemed Corporation ( NYSE:CHE ) shareholders, because the company has just released its...Chemed Corporation (NYSE:CHE) Shares Could Be 38% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$707 Chemed is estimated to be...Chemed Corp: Genius Of The Model Lies In Its Corporate Strategy
Summary Chemed Corp's unconventional structure is masterfully managed with a disciplined focus on operational excellence and shareholder-friendly capital allocation. The company's primary competitive advantage is its brand, a powerful intangible asset cultivated over nearly a century of reliable service and effective marketing. Chemed has constructed a uniquely durable enterprise built to create shareholder value for the long term. Read the full article on Seeking AlphaNew Florida CON Sites Will Advance Home-Based And Hospice Care
Chemed’s modest price target increase to $582.25 reflects stable sentiment, as core metrics like future P/E and revenue growth remain virtually unchanged. What's in the News Increased equity buyback authorization by $300 million, bringing total to $2.75 billion.Rendement pour les actionnaires
| CHE | US Healthcare | US Marché | |
|---|---|---|---|
| 7D | -0.8% | 0.03% | -0.7% |
| 1Y | 9.3% | 39.5% | 15.3% |
Rendement vs Industrie: CHE a sous-performé le secteur US Healthcare qui a rapporté 39.5 % au cours de l'année écoulée.
Rendement vs marché: CHE a sous-performé le marché US qui a rapporté 15.3 % au cours de l'année écoulée.
Volatilité des prix
| CHE volatility | |
|---|---|
| CHE Average Weekly Movement | 3.0% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: CHE n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de CHE ( 3% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1970 | 15,811 | Kevin McNamara | www.chemed.com |
Chemed Corporation fournit des services de soins palliatifs aux patients par l'intermédiaire d'un réseau de médecins, d'infirmières diplômées, d'aides à domicile, de travailleurs sociaux, de membres du clergé et de bénévoles, principalement aux États-Unis. La société opère à travers deux segments : VITAS et Roto-Rooter. La société offre des services de plomberie, de nettoyage des canalisations, d'excavation, de restauration de l'eau et d'autres services connexes aux clients résidentiels et commerciaux par l'intermédiaire de succursales appartenant à la société, d'entrepreneurs indépendants et de franchisés.
Chemed Corporation Résumé des fondamentaux
| CHE statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$6.76b |
| Bénéfices(TTM) | US$259.78m |
| Recettes(TTM) | US$2.54b |
Le site CHE est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CHE compte de résultat (TTM) | |
|---|---|
| Recettes | US$2.54b |
| Coût des recettes | US$1.72b |
| Marge brute | US$822.54m |
| Autres dépenses | US$562.75m |
| Les revenus | US$259.78m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Jul 28, 2026
| Résultat par action (EPS) | 19.65 |
| Marge brute | 32.38% |
| Marge bénéficiaire nette | 10.23% |
| Ratio dettes/capitaux propres | 10.8% |
Quelles ont été les performances à long terme de CHE?
Voir les performances historiques et les comparaisonsDividendes
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/27 12:57 |
| Cours de l'action en fin de journée | 2026/07/27 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Chemed Corporation est couverte par 10 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Adam Feinstein | Barclays |
| Joanna Sylvia Gajuk | BofA Global Research |
| Peter Martin | Citizens JMP Securities, LLC |